The Trump administration’s Centers for Medicare & Medicaid Services (CMS) has signaled that it will be revamping the process of negotiating prices for certain Medicare Part D drugs with input f | The agency said it is "considering opportunities to bring greater transparency" and will consider stakeholder feedback on the program.

The U.S. government said on Wednesday it will aim for "greater transparency" in Medicare drug price negotiations under President Donald Trump's administration following criticism from the pharmaceutical industry for the Biden-era law.

Democrats sought answers from RFK Jr. on how the Trump administration would handle Medicare price negotiations after a short CMS statement didn’t clear things up.

Trump has reversed some of President Biden’s initiatives, including $2 monthly out-of-pocket cap on some generics and experimental pricing models for gene therapies. But so far the healthcare elements of the Inflation Reduction Act remain unchanged.

The U.S. government said on Wednesday it will consider opportunities to "bring greater transparency" for the Medicare drug price negotiation program under President Donald Trump's administration. The price negotiation process was established under former President Joe Biden's signature Inflation Reduction Act in 2022.

A letter from several Democratic Senators urged Trump to use his deal-making skills to “flat out reject any request to end negotiations."

Through the issuance of Inauguration Day executive orders, the Trump Administration signaled its apparent intent to tackle drug pricing reforms

Robert F. Kennedy Jr. said he would follow the Trump administration’s orders on prescription drug price negotiations, a process that is overseen by the Centers for Medicare and Medicaid Services. He said he would focus on fighting chronic disease,